Pathological α-synuclein Recruits LRRK2 Expressing Pro-inflammatory Monocytes to the Brain
Overview
Neurology
Authors
Affiliations
Background: Leucine rich repeat kinase 2 (LRRK2) and SNCA are genetically linked to late-onset Parkinson's disease (PD). Aggregated α-synuclein pathologically defines PD. Recent studies identified elevated LRRK2 expression in pro-inflammatory CD16+ monocytes in idiopathic PD, as well as increased phosphorylation of the LRRK2 kinase substrate Rab10 in monocytes in some LRRK2 mutation carriers. Brain-engrafting pro-inflammatory monocytes have been implicated in dopaminergic neurodegeneration in PD models. Here we examine how α-synuclein and LRRK2 interact in monocytes and subsequent neuroinflammatory responses.
Methods: Human and mouse monocytes were differentiated to distinct transcriptional states resembling macrophages, dendritic cells, or microglia, and exposed to well-characterized human or mouse α-synuclein fibrils. LRRK2 expression and LRRK2-dependent Rab10 phosphorylation were measured with monoclonal antibodies, and myeloid cell responses to α-synuclein fibrils in R1441C-Lrrk2 knock-in mice or G2019S-Lrrk2 BAC mice were evaluated by flow cytometry. Chemotaxis assays were performed with monocyte-derived macrophages stimulated with α-synuclein fibrils and microglia in Boyden chambers.
Results: α-synuclein fibrils robustly stimulate LRRK2 and Rab10 phosphorylation in human and mouse macrophages and dendritic-like cells. In these cells, α-synuclein fibrils stimulate LRRK2 through JAK-STAT activation and intrinsic LRRK2 kinase activity in a feed-forward pathway that upregulates phosphorylated Rab10. In contrast, LRRK2 expression and Rab10 phosphorylation are both suppressed in microglia-like cells that are otherwise highly responsive to α-synuclein fibrils. Corroborating these results, LRRK2 expression in the brain parenchyma occurs in pro-inflammatory monocytes infiltrating from the periphery, distinct from brain-resident microglia. Mice expressing pathogenic LRRK2 mutations G2019S or R1441C have increased numbers of infiltrating pro-inflammatory monocytes in acute response to α-synuclein fibrils. In primary cultured macrophages, LRRK2 kinase inhibition dampens α-synuclein fibril and microglia-stimulated chemotaxis.
Conclusions: Pathologic α-synuclein activates LRRK2 expression and kinase activity in monocytes and induces their recruitment to the brain. These results predict that LRRK2 kinase inhibition may attenuate damaging pro-inflammatory monocyte responses in the brain.
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.
Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.
PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.
Ngo H, Srivastava A, Le H, Ayer S, Crotty G, Schwarzschild M BMC Neurosci. 2025; 26(1):19.
PMID: 40038582 PMC: 11877714. DOI: 10.1186/s12868-025-00939-7.
Sokratian A, Zhou Y, Tatli M, Burbidge K, Xu E, Viverette E Sci Adv. 2024; 10(44):eadq3539.
PMID: 39485845 PMC: 11800946. DOI: 10.1126/sciadv.adq3539.
LRRK2 in Parkinson's disease: upstream regulation and therapeutic targeting.
Xiong Y, Yu J Trends Mol Med. 2024; 30(10):982-996.
PMID: 39153957 PMC: 11466701. DOI: 10.1016/j.molmed.2024.07.003.
Boles J, Uriarte Huarte O, Tansey M Res Sq. 2024; .
PMID: 38883776 PMC: 11177977. DOI: 10.21203/rs.3.rs-4478250/v1.